Navigation Links
Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say
Date:11/30/2007

SANTA MONICA, Calif., Nov. 30 /PRNewswire-USNewswire/ -- California's stem cell agency is inviting for-profit companies to apply for research grants for the first time, the Foundation for Taxpayer and Consumer Rights (FTCR) noted today and the non-partisan, non-profit consumer advocacy organization vowed to scrutinize the awards process to prevent abuse.

The California Institute for Regenerative Medicine (CIRM) has just issued calls for applications for two types of grants. CIRM said it planned to fund up to 20 six-month disease team planning grants for a total of $1.1 million. The stem cell agency has also ear marked $25 million for up to 16 three-year grants to develop new stem cell lines.

"We've already seen an example of an improper attempt by a stem cell board member to influence an award to his non-profit research institution," said John M. Simpson, FTCR's Stem Cell Project Director. "The possibility of abuse is even greater when the biotech industry goes after the money."

Researchers from both universities and companies will compete head-to-head for the grants. CIRM staff have vowed that only the quality of the science in the proposed projects will determine who gets the money. The grants will be awarded in the spring.

So far CIRM has awarded about $210 million in research, training and facilities grants. All that money has gone to universities and non-profit research institutions. When Californians approved Proposition 71 funding the state's $6-billion stem cell project, they approved giving money to companies as well as universities and research institutions.

Companies have not been able to apply for grants because the Intellectual Property (IP) regulations governing who controls any discoveries made with CIRM-funded research had not been created for businesses. Those IP rules are expected to be approved at the stem cell oversight board's December meeting.

"Biotech companies will clearly play an important role in stem cell research," said Simpson. "Californians voted to allow them to seek CIRM funds, but at the same time they didn't authorize a blank check for biotech. We will continue to watch CIRM and the oversight committee closely and work to ensure that those who are paying for this research -- the people of California -- have affordable access to any discoveries that are made."

This week Controller John Chiang announced that he planned to audit CIRM. He also asked the Fair Political Practices Commission to investigate board member John Reed's intervention in a grant application from the Burnham Institute for Medical Research where he is president. "I am delighted to see Controller Chiang exercising his oversight responsibility so effectively," said Simpson.

FTCR's Stem Cell Oversight and Accountability Project is working to ensure that California's landmark stem cell research program offers accessible and affordable cures and treatments to the taxpayers who have funded it. The program will award $3 billion in grants over a decade. Bond financing charges mean the project, the largest source of stem cell research funding in the world, will cost California taxpayers $6 billion.

The Foundation for Taxpayer and Consumer Rights is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at: http://www.ConsumerWatchdog.org.


'/>"/>
SOURCE Foundation for Taxpayer and Consumer Rights
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Experiments Get Close to Out-of-Body Experience
2. HEI, Inc. Closes on Sale of RFID Division Assets
3. PSI Brings its Pioneering Efforts to a Close
4. Acute lung injury patients one-third less likely to die in closed model ICUs
5. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
6. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
7. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
8. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
9. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
10. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
11. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: